

Clinical Trials in Kazakhstan

Y 2023 Research report

Location Data

Kazakhstan is the second largest country between all of the former Soviet Union republics with its population of **19,5 million people^[1]**. The country has a large and very diverse population, with a sufficient number of trained workers in Healthcare industry.

- Ethnically diverse treatment-naïve patient population.
- Most of the population is concentrated in a few major cities, where healthcare centers are usually well-equipped medical facilities.
- Motivated patient population in search of better care.
- Moderate investigator fees.
- Low number of studies per patient



Russia, together with Kazakhstan, Belarus, Armenia and Kyrgyzstan as members of Eurasian Economic Union concluded the agreement of unified principles and rules for circulation of drugs and medical devices entered into force on 12 Feb 2016, which facilitated clinical trials conduct in these countries and made it transparent to partners.

There is an opportunity for pharmaceutical companies and CROs of unified electronic drug registration within the Union: when it is possible to run clinical trials in one

of the member states and then apply for marketing authorization in any of the remaining participating countries through a simplified procedure.

For clients that are looking to initiate new studies and prefer to avoid potential study conduct challenges in the Russian Federation, Kazakhstan offers a cost-effective alternative location. SRG was the first CRO to establish itself in Kazakhstan and has 15 years' experience in delivering high quality clinical trials.


Trial Data

During the Year 2023 there were 15 clinical trials initiated in Kazakhstan including local studies. That represents a 25% increase rate in comparison with the previous year when 12 studies were initiated. Most clinical trials conducted in Kazakhstan in the Year 2023 were interventional studies with a 67% market share.

Among interventional studies, the dominant type of intervention was drug (6 studies), followed by behavioral (3) and procedure (1) intervention types.

The dominant therapy areas of interventional clinical trials (intervention type – drug) initiated in Kazakhstan during the Year 2023 include Cardiology, Gastroenterology, General Practice, Infectious diseases, Obstetrics and Oncology.

Clinical Trials in Kazakhstan (Y 2016 - Y 2023)



The most prevalent Phases of clinical trials conducted in Kazakhstani sites by total number of studies were Phase I and Phase II, with a 33% share each.

Sponsor Data

The U.S. was the key (and the only) international player in clinical trials initiated in Kazakhstan during the Year 2023, with a market share of 20% - almost the same figure as in the Year 2022 (17%).

Combined market share based on total studies conducted by both sponsors and CROs, and by both international and Kazakhstani sponsors.

International Trial Sponsors in Kazakhstan in Y 2023

Nº	Site Name	No. Studies	No. Subjects
1	Bayer	1	9,300
2	Yale University	1	900
3	Columbia University	1	216
Combined share		20%	83%

Kazakhstani Trial Sponsors in Kazakhstan in Y 2023


Nº	Site Name	No. Studies	No. Subjects
1	Kazakhstan's Medical University "KSPH"	2	1,034
2	Kazakh Association of Internal Medicine Specialists	2	392
3	Nazarbayev University	2	238
4	Karaganda Medical University	1	180
5	LeKos LLP	1	126
6	Scientific Center for Anti-infectious Drugs, Kazakhstan	1	62
7	University Medical Center, Kazakhstan	1	60
8	National Scientific Center of Traumatology and Orthopedics n.a. academician N.D. Batpenov	1	40
9	Industrial Microbiology LLP	1	20
Combined market share of these companies		80%	17%

Subject Data

The overall number of subjects enrolled (or planned to be enrolled) in clinical trials initiated in Kazakhstan during the Year 2023 reached a total of 12,568 subjects – a shoot up in comparison with the previous year when only 507 subjects were enrolled.

The most prevalent Phase of clinical trials by the number of participating subjects was Phase III with 89% (9,300) of all subjects enrolled. 950 subjects were enrolled (or planned to be enrolled) into observational studies, and 1,216 subjects – in interventional clinical trials without FDA-defined phases (from I to IV) during the same year.

Breakdown of Number of Subjects Enrolled by Phase



About The Orange Paper

The Orange Paper is a free publication produced by Synergy Research Group for the pharmaceutical industry since 2007. It pulls together data from numerous public sources into a single brief document to aid decision makers planning to conduct clinical trials.

This edition of the Orange Paper uses data from clinicaltrials.gov, all of the data within this document are actual on date: 02/03/2023.

About Synergy Research Group

Synergy Research Group is a contract research organization successfully operating in Russia since 2002 and Kazakhstan since 2007.

For all of clinical studies conducted by our company we've set up the highest level of world-class quality both for SOPs and for final study data.

From year to year our company is the one of market leaders by the numbers of conducted clinical studies and enrolled patients.

We're continuously working on improvements of our SOPs, study risk management and IT infrastructure – and replacing an outdated R&D strategies by novel, more efficient approaches to clinical research.

The high recruitment rates of the emerging markets combined with innovative technology allows Synergy to offer our clients conduct faster, more cost-effective studies without sacrificing quality for our clients.